Keywords: CANAGLIFLOZIN; Response correlation method; Advanced balance point using spectrum subtraction method; Advanced amplitude modulation method; Advanced absorbance subtraction method; Canagliflozin; Metformin hydrochloride;
مقالات ISI CANAGLIFLOZIN (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: CANAGLIFLOZIN; Canagliflozin; Empagliflozin; Extended ratio subtraction; Linagliptin; Metformin; Ratio difference; UV spectrophotometry; Validation;
Keywords: CANAGLIFLOZIN; type 2 diabetes; sodium-glucose cotransporter 2 inhibitors; cardiovascular safety; canagliflozin; dapagliflozin; empagliflozin; diabète de type 2; inhibiteurs du cotransporteur sodium-glucose de type 2; innocuité sur le plan cardiovasculaire; canagliflo
Keywords: CANAGLIFLOZIN; Canagliflozin; SGLT2 inhibitor; SGLT1 inhibitor; Kidney tumors; Pheochromocytomas; Adrenal medullary hyperplasia; Carbohydrate malabsorption;
Keywords: CANAGLIFLOZIN; Diabetes mellitus tipo 2 (DM2); Cotransportador sodio-glucosa tipo 2 (SGLT2); Inhibidores del SGLT2 (iSGLT2); Dapagliflozina; Canagliflozina; Empagliflozina; GuÃas de práctica clÃnica; Red de Grupos de Estudio de la Diabetes en; Atención Primaria de l
Keywords: CANAGLIFLOZIN; SGLT2 inhibitor; DPP4 inhibitor; Canagliflozin; Combination treatment; Glucagon-like peptide-1; aGLP-1; active GLP-1; ANOVA; Analysis of variance; AUC; Area under the curve; CMA; (2S)-2-Cyano-1-[trans-4-(morpholinocarbonyl)cyclohexylamino]acetylpyrrolidin
Keywords: CANAGLIFLOZIN; SGLT2 Inhibitors; Dapagliflozin; Canagliflozin; Empagliflozin; CANVAS; CREDENCE; DECLARE-TIMI 58; Cardiovascular outcomes; Nonglycemic benefit of SGLT2 inhibitors;
Keywords: CANAGLIFLOZIN; Canagliflozin; Berberine; Diabetes mellitus; AMP-activated protein kinase; Sodium-glucose cotransporter-2
Keywords: CANAGLIFLOZIN; canagliflozin; India; pharmacodynamics; pharmacokinetics; safety;
Keywords: CANAGLIFLOZIN; canagliflozin; diabetes; glycemic control; HbA1c; Medicare; SGLT2 inhibitors;
Keywords: CANAGLIFLOZIN; Canagliflozin; Teneligliptin; Combination treatment; Glucagon-like peptide-1; Zucker diabetic fatty rats
Keywords: CANAGLIFLOZIN; canagliflozin; composite quality measures; diabetes; quality measures; sitagliptin; T2DM;
Keywords: CANAGLIFLOZIN; canagliflozin; pharmacodynamics; pharmacokinetics; safety; sodium-glucose cotransporter 2 inhibitor;
Keywords: CANAGLIFLOZIN; canagliflozin; dapagliflozin; empagliflozin; sodium-glucose co-transporter 2 inhibitor;
Keywords: CANAGLIFLOZIN; canagliflozin; ESRD; hepatic impairment; pharmacokinetics; renal impairment; T2DM;
Keywords: CANAGLIFLOZIN; Type 2 diabetes mellitus; Sodium glucose co-transporter 2 (SGLT2) inhibitor; Canagliflozin; Metformin; Twice daily (BID)
Keywords: CANAGLIFLOZIN; Diabetes mellitus (DM); diabetic nephropathy (DN); hyperfiltration; glomerular filtration rate (GFR); proximal tubule; sodium/glucose cotransport; sodium/glucose cotransporter 2 (SGLT2); SGLT2 inhibitor; canagliflozin; dapagliflozin;
Keywords: CANAGLIFLOZIN; obesity; diabetes; dyslipidemia; exenatide extended-release; dapagliflozin; canagliflozin; Icosapent ethyl;
Keywords: CANAGLIFLOZIN; Body weight reduction; Canagliflozin; Glycaemic control; Liver function tests; Sodium glucose co-transporter 2 inhibitor; Type 2 diabetes mellitusAE, adverse event; ALT, alanine aminotransferase; ANCOVA, analysis of covariance; AP, alkaline phosphatase; A
Keywords: CANAGLIFLOZIN; Canagliflozin; Metformin; Diabetic rat; Cortex; Acetylcholinesterase; NeurotransmittersCAN, canagliflozin; MET, metformin; C, control; D, diabetic group that did not receive treatment; DM, Diabetes mellitus; T2DM, type 2 diabetes mellitus; BBB, blood-brai
Ion-pair solid phase extraction for the simultaneous separation and quantitation of metformin and canagliflozin in human plasma by LC-MS/MS
Keywords: CANAGLIFLOZIN; Metformin; Canagliflozin; Ion-pair solid phase extraction; Human plasma; LC-MS/MS; Pharmacokinetics;
SGLT1 inhibition: Pros and cons
Keywords: CANAGLIFLOZIN; SGLT1; SGLT2; Sotagliflozin; Canagliflozin; Glycosuria;
Effects of canagliflozin versus glimepiride on adipokines and inflammatory biomarkers in type 2 diabetes
Keywords: CANAGLIFLOZIN; ANCOVA; analysis of covariance; CANA; canagliflozin; CANVAS; CANagliflozin cardioVascular Assessment Study; CI; confidence interval; CRP; C-reactive protein; GLIM; glimepiride; HDL-C; high-density lipoprotein cholesterol; IL-6; interleukin-6; LDL-C; low-d
Canagliflozin exerts anti-inflammatory effects by inhibiting intracellular glucose metabolism and promoting autophagy in immune cells
Keywords: CANAGLIFLOZIN; AMPK; AMP-activated protein kinase; pAMPK; phosphor-AMPK; CAN; canagliflozin; 2-DG; 2-deoxy-d-glucose; ECAR; extracellular acidification rate; ELISA; enzyme linked immunosorbent assay; IL-1; interleukin-1; IL-6; interleukin-6; LC3; microtubule-associated
Canagliflozin protects against non-alcoholic steatohepatitis in type-2 diabetic rats through zinc alpha-2 glycoprotein up-regulation
Keywords: CANAGLIFLOZIN; Non-alcoholic steatohepatitis; Diabetes mellitus; SGLT2 inhibitor; Canagliflozin; Zinc-α2-glycoprotein;
Euglycemic Diabetic Ketoacidosis with Elevated Acetone in a Patient Taking a Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitor
Keywords: CANAGLIFLOZIN; sodium-glucose cotransporter-2 inhibitors; SGLT2; euglycemic diabetic ketoacidosis; acetone; canagliflozin;
Canagliflozin potentiates GLP-1 secretion and lowers the peak of GIP secretion in rats fed a high-fat high-sucrose diet
Keywords: CANAGLIFLOZIN; Diet-induced obesity; Canagliflozin; Glucagon-like peptide-1; Glucose-dependent insulinotropic polypeptide; Sodium-glucose cotransporter 1(SGLT1); SGLT2 inhibitor; DPP-IV; dipeptidyl peptidase-IV; GLP-1; glucagon-like peptide-1; GIP; Glucose-dependent i
Canagliflozin prevents scopolamine-induced memory impairment in rats: Comparison with galantamine hydrobromide action
Keywords: CANAGLIFLOZIN; Canagliflozin; Scopolamine; AChE; Monoamines; M1 mAChR;
Real-world Clinical Outcomes Among Patients With Type 2 Diabetes Receiving Canagliflozin at a Specialty Diabetes Clinic: Subgroup Analysis by Baseline HbA1c and Age
Keywords: CANAGLIFLOZIN; canagliflozin; effectiveness; real-world evidence; sodium glucose co-transporter 2 inhibitor; type 2 diabetes mellitus;
EMPA-REG OUTCOME: The Nephrologist's Point of View
Keywords: CANAGLIFLOZIN; Canagliflozin; Dapagliflozin; Empagliflozin; Renal outcomes; Renoprotection; Sodium glucose cotransporter 2 inhibitors;
The impact of SGLT2 inhibitors, compared with insulin, on diabetic bone disease in a mouse model of type 1 diabetes
Keywords: CANAGLIFLOZIN; Bone microarchitecture; Cortical bone; Trabecular bone; Glycosuria; Hypercalciuria; Canagliflozin; Dapagliflozin;
HbA1c Outcomes in Patients Treated With Canagliflozin Versus Sitagliptin in US Health Plans
Keywords: CANAGLIFLOZIN; canagliflozin; diabetes; glycosylated hemoglobin; HbA1c; sitagliptin;
Canagliflozin in Conjunction With Sulfonylurea Maintains Glycemic Control and Weight Loss Over 52 Weeks: A Randomized, Controlled Trial in Patients With Type 2 Diabetes Mellitus
Keywords: CANAGLIFLOZIN; canagliflozin; cardiovascular disease; SGLT2 inhibitor; sulfonylureas; type 2 diabetes; weight loss;
Systematic review of metformin monotherapy and dual therapy with sodium glucose co-transporter 2 inhibitor (SGLT-2) in treatment of type 2 diabetes mellitus
Keywords: CANAGLIFLOZIN; SGLT2 inhibitors; Dapagliflozin; Canagliflozin; Empagliflozin; Metformin; Type 2 diabetes mellitus; HbA1c;
Resolving the KgA1c paradox in the management of type 2 diabetes mellitus
Keywords: CANAGLIFLOZIN; Canagliflozin; Dapagliflozin; Empagliflozin; KgA1c paradox; Overweight; SGLT2 inhibitors; Type 2 diabetes mellitus;
Model analysis of effect of canagliflozin (Invokana), a sodium-glucose cotransporter 2 inhibitor, to alter plasma 1,5-anhydroglucitol
Keywords: CANAGLIFLOZIN; Diabetes; Canagliflozin; Invokana; SGLT2 inhibitors; Anhydroglucitol; Mathematical model;
Real-world Canagliflozin Utilization: Glycemic Control Among Patients With Type 2 Diabetes Mellitus-A Multi-Database Synthesis
Keywords: CANAGLIFLOZIN; canagliflozin; goal attainment; HbA1c levels; real-world; sodium glucose co-transporter 2 inhibitor; type 2 diabetes mellitus;
SGLT2 inhibitor therapy improves blood glucose but does not prevent diabetic bone disease in diabetic DBA/2J male mice
Keywords: CANAGLIFLOZIN; Diabetic bone disease; Type 1 diabetes; Trabecular bone; Cortical bone; Microarchitecture; Canagliflozin;
SGLT2 inhibitors: their potential reduction in blood pressure
Keywords: CANAGLIFLOZIN; Canagliflozin; dapagliflozin; empagliflozin; hypertension
Efficacy and safety of canagliflozin by baseline HbA1c and known duration of type 2 diabetes mellitus
Keywords: CANAGLIFLOZIN; Type 2 diabetes mellitus; Canagliflozin; Sodium glucose co-transporter 2 inhibitor; Glycemic control; Efficacy; Safety;
Rapid determination of canagliflozin in rat plasma by UHPLC–MS/MS using negative ionization mode to avoid adduct-ions formation
Keywords: CANAGLIFLOZIN; Canagliflozin; UHPLC–MS/MS; Adduct ions; Pharmacokinetics; Rat plasma
Les inhibiteurs de SGLT2 : pour quels patients ? Quelle place dans la stratégie thérapeutique ?
Keywords: CANAGLIFLOZIN; Diabète de type 2; Inhibiteurs de SGLT2; Glycosurie; Dapaglifozine; Canagliflozine; Empaglifozine; Type 2 diabetes; SGLT2 inhibitors; Glucosuria; Dapaglifozin; Canagliflozin; Empaglifozin;
Metabolic effects of SGLT-2 inhibitors beyond increased glucosuria: A review of the clinical evidence
Keywords: CANAGLIFLOZIN; Canagliflozin; Dapagliflozin; Empagliflozin; Energy balance; Glucotoxicity; Insulin secretion; Insulin sensitivity; Type 2 diabetes
The design and synthesis of novel SGLT2 inhibitors: C-glycosides with benzyltriazolopyridinone and phenylhydantoin as the aglycone moieties
Keywords: CANAGLIFLOZIN; Triazolopyridinone; Hydantoin; SGLT2; Canagliflozin; Dapagliflozin; Glucoside;
Effects of Hydrochlorothiazide on the Pharmacokinetics, Pharmacodynamics, and Tolerability of Canagliflozin, a Sodium Glucose Co-transporter 2 Inhibitor, in Healthy Participants
Keywords: CANAGLIFLOZIN; canagliflozin; diuretic; drug-drug interaction; hydrochlorothiazide; pharmacodynamics; pharmacokinetics; sodium glucose co-transporter 2 (SGLT2) inhibitor; type 2 diabetes mellitus;
SGLT2 inhibitors in the treatment of type 2 diabetes
Keywords: CANAGLIFLOZIN; Type 2 diabetes; Glucose reabsorption; SGLT2 inhibitors; Dapagliflozin; Canagliflozin; EmpagliflozinHbA1c, hemoglobin A1c; FRG, familial renal glucosuria; GLUT, glucose transporter; eGFR, estimated glomerular filtration rate; FPG, fasting plasma glucose;
C-Glucosides with heteroaryl thiophene as novel sodium-dependent glucose cotransporter 2 inhibitors
Keywords: CANAGLIFLOZIN; Type 2 diabetes; SGLT2 inhibitor; Thiophene; Glucoside; Canagliflozin;